Pasithea Therapeutics Corp. (KTTA) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Pasithea Therapeutics Corp. on December 15, 2025, regarding an event reported on December 12, 2025. The Company is an emerging growth company incorporated in Delaware, with its principal executive offices in Miami Beach, Florida. Its common stock (KTTA) and warrants (KTTAW) trade on The Nasdaq Capital Market.
Key Financial Metrics
This filing is a current report regarding a corporate event and does not contain financial statements. The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The primary material change reported is the resolution of a Nasdaq listing compliance issue. On June 23, 2025, the Company received notice of non-compliance with Nasdaq Listing Rule 5550(a)(2) regarding the $1.00 minimum bid price requirement. The Company was granted a 180-day compliance period ending December 22, 2025. As of December 12, 2025, the Company successfully regained compliance by maintaining a closing bid price at or above $1.00 per share for the required number of consecutive business days.
Guidance, Outlook, and Risks
The filing confirms that the matter regarding the minimum bid price requirement is now closed. No new guidance, outlook, management commentary on operations, or discussion of new risks or contingencies is provided in this specific report.
Key Facts for Investor Verification
- The Company has resolved its Nasdaq minimum bid price deficiency as of December 12, 2025.
- The stock price has maintained the required $1.00 threshold for the necessary consecutive trading days.
- No financial performance data is included in this filing; investors should refer to the most recent 10-K or 10-Q for financial metrics.
- The Company remains listed on The Nasdaq Capital Market under the symbols KTTA and KTTAW.